Shots:

• The MAA submission follows the results of P-II DELPHI study- DELPHI-Extension study- P-III DELOS (1-5) study and SYROS study. The collective studies result demonstrated that Puldysa (idebenone) is showing clinical benefits & long-term efficacy in patients with DMD
• Santhera also plans to submit NDA to the FDA following the completion of P-III SIDEROS study assessing Puldysa (Idebenone) in 266 patients with DMD administering glucocorticoid steroids from 18mos. across 60 sites including Europe- the US and Israel
• Puldysa (Idebenone) is a chemical analog of benzoquinone and a co-factor for quinone oxidoreductase (NQO1) and has received the ODD designation in Europe- the US- Switzerland & Australia and a FT designation by the US FDA

Ref: Santhera | Image: Santhera